Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages

被引:20
作者
Mor, N [1 ]
Simon, B [1 ]
Heifets, L [1 ]
机构
[1] NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206
关键词
D O I
10.1128/AAC.40.6.1482
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Inhibitory and bactericidal activities of KRM-1648 were determined against Mycobacterium tuberculosis and M. avium residing in human monocyte-derived macrophages and extracellular M, tuberculosis and M. avium. MICs and MBCs of KRM-1648 against intracellular and extracellular bacteria were substantially lower than those of rifampin. The MICs and MBCs of either drug against the intracellular bacteria were only twofold lower than or equal to the values found for extracellular bacteria. The prolonged effect of KRM-1648 found in this study is probably associated with high ratios of intracellular accumulation, which were 50- to 100-fold higher than that found for rifampin, Further studies on intracellular distribution of KRM-1648 and on the sites of actual interaction between the drug and bacteria residing in macrophages are necessary, as well as evaluation of combined effects of KRM-1648 with other drugs in long-term macrophage culture experiments.
引用
收藏
页码:1482 / 1485
页数:4
相关论文
共 16 条
[1]   ACTIVITY INVITRO OF RIFABUTIN, FCE-22807, RIFAPENTINE, AND RIFAMPIN AGAINST MYCOBACTERIUM-MICROTI AND MYCOBACTERIUM-TUBERCULOSIS AND THEIR PENETRATION INTO MOUSE PERITONEAL-MACROPHAGES [J].
DHILLON, J ;
MITCHISON, DA .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 145 (01) :212-214
[2]   INVITRO OBSERVATIONS ON THE SUITABILITY OF NEW RIFAMYCINS FOR THE INTERMITTENT CHEMOTHERAPY OF TUBERCULOSIS [J].
DICKINSON, JM ;
MITCHISON, DA .
TUBERCLE, 1987, 68 (03) :183-193
[3]   INVITRO PROPERTIES OF RIFAPENTINE (MDL473) RELEVANT TO ITS USE IN INTERMITTENT CHEMOTHERAPY OF TUBERCULOSIS [J].
DICKINSON, JM ;
MITCHISON, DA .
TUBERCLE, 1987, 68 (02) :113-118
[4]  
DICKINSON JM, 1981, AM REV RESPIR DIS, V145, P212
[5]   BACTERICIDAL ACTIVITY INVITRO OF VARIOUS RIFAMYCINS AGAINST MYCOBACTERIUM-AVIUM AND MYCOBACTERIUM-TUBERCULOSIS [J].
HEIFETS, LB ;
LINDHOLMLEVY, PJ ;
FLORY, MA .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1990, 141 (03) :626-630
[6]  
HEIFETS LB, 1985, ANTIMICROB AGENTS CH, V28, P570, DOI 10.1128/AAC.28.4.570
[7]   IN-VITRO AND IN-VIVO ACTIVITIES OF THE BENZOXAZINORIFAMYCIN KRM-1648 AGAINST MYCOBACTERIUM-TUBERCULOSIS [J].
HIRATA, T ;
SAITO, H ;
TOMIOKA, H ;
SATO, K ;
JIDOI, J ;
HOSOE, K ;
HIDAKA, T .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (10) :2295-2303
[8]   INVIVO ACTIVITIES OF NEWER RIFAMYCIN ANALOGS AGAINST MYCOBACTERIUM-AVIUM INFECTION [J].
KLEMENS, SP ;
CYNAMON, MH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (10) :2026-2030
[9]   IN-VITRO ACTIVITY OF THE BENZOXAZINORIFAMYCIN KRM-1648 AGAINST DRUG-SUSCEPTIBLE AND MULTIDRUG-RESISTANT TUBERCLE-BACILLI [J].
LUNAHERRERA, J ;
REDDY, MV ;
GANGADHARAM, PRJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (02) :440-444
[10]   METHODS FOR DETERMINING CONCENTRATIONS OF ANTIMICROBIAL AGENTS IN HUMAN MONOCYTES [J].
MOR, N ;
SIMON, B ;
HEIFETS, L .
JOURNAL OF CHEMOTHERAPY, 1995, 7 (03) :207-209